FLT3 and acute myeloid leukemia: In the Phase III ADMIRAL trial, adult patients with R/R FLT3-mutated AML treated with gilteritinib had a significantly longer median overall survival and higher response rates compared with patients receiving standard salvage chemotherapy [4,5].